⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
APLLTD - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.2
| Stock Code | APLLTD | Market Cap | 13,273 Cr. | Current Price | 676 ₹ | High / Low | 1,108 ₹ |
| Stock P/E | 26.2 | Book Value | 267 ₹ | Dividend Yield | 1.63 % | ROCE | 11.3 % |
| ROE | 9.68 % | Face Value | 2.00 ₹ | DMA 50 | 758 ₹ | DMA 200 | 860 ₹ |
| Chg in FII Hold | 0.19 % | Chg in DII Hold | -0.13 % | PAT Qtr | 149 Cr. | PAT Prev Qtr | 179 Cr. |
| RSI | 25.7 | MACD | -26.7 | Volume | 50,753 | Avg Vol 1Wk | 43,586 |
| Low price | 665 ₹ | High price | 1,108 ₹ | PEG Ratio | -7.92 | Debt to equity | 0.27 |
| 52w Index | 2.41 % | Qtr Profit Var | 74.0 % | EPS | 24.0 ₹ | Industry PE | 27.6 |
📊 Financials
- Revenue & Profitability: PAT declined from ₹179 Cr. to ₹149 Cr., showing weakness. EPS at ₹24.0 is modest relative to valuation.
- Margins & Returns: ROCE at 11.3% and ROE at 9.68% are below industry averages, reflecting weak efficiency.
- Debt & Liquidity: Debt-to-equity ratio of 0.27 indicates moderate leverage, manageable but not ideal.
- Cash Flow: Dividend yield of 1.63% provides some shareholder returns.
💹 Valuation
- P/E Ratio: 26.2 vs Industry PE of 27.6 — fairly valued compared to peers.
- P/B Ratio: Current price ₹676 vs Book Value ₹267 — ~2.5x book value, reasonable for pharma sector.
- PEG Ratio: -7.92 — negative PEG indicates poor growth outlook relative to valuation.
- Intrinsic Value: Current price is near fair value, offering limited upside.
🏢 Business Model & Competitive Advantage
- Pharmaceutical manufacturing with diversified product portfolio.
- Moderate debt and stable dividend policy provide resilience.
- Weak ROCE and ROE limit competitive advantage compared to peers.
📈 Entry Zone & Long-Term Guidance
- Entry Zone: Attractive accumulation range between ₹665 – ₹700, near its 52-week low.
- Long-Term Holding: Fundamentals are average, valuations fair. Suitable for cautious accumulation with long-term horizon, but monitor profitability trends.
✅ Positive
- Dividend yield of 1.63% provides shareholder returns.
- FII holdings increased slightly (+0.19%), showing foreign investor interest.
- Stock trading near 52-week low offers accumulation opportunity.
⚠️ Limitation
- Weak ROCE (11.3%) and ROE (9.68%) compared to industry standards.
- Negative PEG ratio (-7.92) indicates poor growth outlook.
- Quarterly PAT decline shows earnings weakness.
📉 Company Negative News
- DII holdings declined by 0.13%, showing reduced domestic institutional confidence.
- RSI at 25.7 and MACD negative (-26.7) reflect bearish technical signals.
📈 Company Positive News
- Dividend yield of 1.63% supports shareholder value.
- FII holdings increased, showing foreign investor confidence.
🏭 Industry
- Pharmaceutical sector benefits from healthcare demand and government support.
- Industry PE at 27.6 is slightly higher than company’s valuation, suggesting fair pricing.
🔎 Conclusion
APLLTD shows moderate fundamentals with fair valuation and stable dividend yield, but suffers from weak efficiency and declining profits. While foreign investors show slight confidence, domestic institutions remain cautious. Best strategy: accumulate cautiously near ₹665–₹700 and hold for long-term gains, but monitor profitability and growth outlook closely.